IP Library Granted Patent US 7,524,504
Granted Patent B1
US 7,524,504 · App. 12/007,655 · Granted Apr 28, 2009

Anti-glycation hydrolysate of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,504
App. No.
12/007,655
Granted
Apr 28, 2009
Kind
B1
Abstract

Methods and compositions for reducing the levels of Advanced Glycation Endproducts (AGE) related proteins in the skin by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Ganoderma lucidum that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei , and thereafter rendered substantially devoid of acid-protease activity.

Claims (10)

1. A topical anti-AGE mushroom hydrolysate substantially devoid of acid protease activity produced by the steps of (a) extracting the water-soluble polysaccharopeptide constituents of Ganoderma lucidum in an acidic aqueous solvent having a pH of from about 3.5 to about 4.5 (b) hydrolysis of the resultant water-soluble polysaccharopeptide extract with an acid protease enzyme of Rhizomucor miehei and (c) inactivation or removal of the acid protease via molecular weight sieve, thermal inactivation and/or pepstatin-affinity gel chromatography.

2. A method for inhibiting the formation of AGE related protein comprising applying to the skin of a mammal a therapeutically-effective amount of a topical anti-AGE mushroom hydrolysate according to claim 1 .

3. The method of claim 2 , where the topical anti-AGE mushroom hydrolysate of claim 1 is applied in a concentration sufficient to increase the expression of mRNA coding for GLO-1 by at least about 33%.

4. The method of claim 2 , where the topical anti-AGE mushroom hydrolysate of claim 1 is applied in a concentration sufficient to increase the expression of mRNA coding for GLO-1 by at least about 40%.

5. The method of claim 2 , where the topical anti-AGE mushroom hydrolysate of claim 1 is applied in a concentration sufficient to increase the expression of mRNA coding for GLO-1 by at least about 50%.

6. A topical anti-AGE mushroom hydrolysate substantially devoid of acid protease activity according to claim 1 wherein the acid protease enzyme of Rhizomucor miehei used to hydrolyze the water-soluble polysaccharopeptide extract of Ganoderma lucidum has from about 4,000 to about 10,000 HUT units of activity per milliliter.

7. A dermatocosmetic composition comprising from about 0.01% to about 10% by weight of a topical anti-AGE mushroom hydrolysate according to claim 1 .

8. A dermatocosmetic composition of claim 7 further comprising at least one additional topical anti-AGE agent.

9. A dermatocosmetic composition of claim 7 wherein the at least one additional topical anti-AGE agent is selected from the group consisting of amino guanidine and carnosine.

10. A dermatocosmetic composition of claim 7 further comprising at least one of a photoprotective agent, an antioxidant.

Assignments (3)
CHANGE OF NAME Recorded Nov 17, 2022
From: ACTIVE ORGANICS, INC.
To: LIPOTEC USA, INC.
Reel/Frame 061810/0923 →
CHANGE OF NAME Recorded Nov 17, 2011
From: ACTIVE ORGANICS, LP
To: ACTIVE ORGANICS, INC.
Reel/Frame 027242/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2010
From: BISHOP, MICHAEL; BISHOP, ELYSIANN; SMITH, WALTER
To: ACTIVE ORGANICS, LP
Reel/Frame 024256/0717 →